Spur Therapeutics
VerifiedBiopharmaceutical focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders.
Launch date
Employees
Market cap
$28.5m
Net debt
$25.5m
Enterprise valuation
$3m (Public information from Feb 2024)
Share price
$6.48 FRLN
Company register number 09500073
Stevenage England (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | - | - | - | - | <1m |
| EBITDA | (20.0m) | (29.2m) | (46.8m) | (77.5m) | (121m) | (88.3m) | - |
| % EBITDA margin | - | (7303 %) | - | - | - | - | - |
| Profit | 10.0m | (30.3m) | (49.0m) | (87.6m) | (128m) | (80.9m) | - |
| % profit margin | - | (7564 %) | - | - | - | - | - |
| R&D budget | - | 31.1m | 42.8m | 69.2m | 86.8m | 60.2m | - |
| R&D % of revenue | - | 7771 % | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$80.0m | Series C | ||
| N/A | $159m Valuation: $467m -9.1x EV/LTM EBITDA | IPO | |
* | $15.0m | Post IPO Convertible | |
* | N/A | Acquisition | |
* | $50.0m | Post IPO Equity | |
| Total Funding | $276m | ||
Recent News about Spur Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.